Moody's: Pfizer's US coronavirus vaccine authorization is credit positive – Reuters
|The US-based rating agency Moody’s Investors Service the Food and Drug Administration (FDA) authorization to Pfizer Inc’s coronavirus vaccine is credit positive for the American pharma giant, per Reuters.
Key takeaways
"The approval is credit positive because of incremental profit and cash flow from sales of the vaccine,"
"The revenue and profit opportunities for Pfizer are significant because it has priced the vaccine at a profit."
This comes after the US medical regulator authorized emergency use of the vaccine early Saturday, following the footsteps of the UK and Canada.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.